Zentalis Pharmaceuticals, Inc.
ZNTLNasdaqCIK 1725160HealthcareFiscal year ends Dec 31
Reports and events: 133 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1416:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-057112 |
| 2026-08-0616:13 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001725160-26-000062 |
| 2026-08-0616:10 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001725160-26-000061 |
| 2026-06-1816:03 ET | 8-K | 5.07 Shareholder vote results | 0001725160-26-000052 |
| 2026-05-2716:07 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001725160-26-000049 |
| 2026-05-2117:29 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000045 |
| 2026-05-1216:11 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001725160-26-000042 |
| 2026-05-1216:10 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001725160-26-000041 |
| 2026-05-0508:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000033 |
| 2026-04-3016:06 ET | DEF 14A | Proxy statementPeriod 2026-06-16 | 0001725160-26-000027 |
| 2026-04-1715:11 ET | 8-K | 7.01 Regulation FD disclosure | 0001725160-26-000020 |
| 2026-04-0908:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000017 |
| 2026-03-2616:46 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001725160-26-000014 |
| 2026-03-2616:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001725160-26-000010 |
| 2026-01-0917:18 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001725160-26-000003 |
| 2026-01-0216:10 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000902664-26-000024 |
| 2025-12-1517:16 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000902664-25-005287 |
| 2025-12-1517:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001725160-25-000164 |
| 2025-11-1016:15 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001725160-25-000161 |
| 2025-11-1016:11 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-25-000159 |
| 2025-08-2616:08 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-25-000154 |
| 2025-08-0616:13 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001725160-25-000149 |
| 2025-08-0616:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001725160-25-000147 |
| 2025-06-1816:09 ET | 8-K | 5.07 Shareholder vote results | 0001725160-25-000127 |
| 2025-06-0206:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-25-000119 |
| 2025-05-2006:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-25-000108 |
| 2025-05-1416:13 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001725160-25-000105 |
| 2025-05-1416:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001725160-25-000104 |
| 2025-04-3016:09 ET | DEF 14A | Proxy statementPeriod 2025-06-17 | 0001725160-25-000092 |
| 2025-04-2806:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-25-000082 |
| 2025-03-2616:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001725160-25-000070 |
| 2025-03-2616:11 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001725160-25-000067 |
| 2025-03-1706:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-25-012899 |
| 2025-01-2909:18 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001725160-25-000013 |
| 2025-01-2816:07 ET | 8-K | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001725160-25-000006 |
| 2024-12-1916:01 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001725160-24-000193 |
| 2024-11-1308:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-24-000177 |
| 2024-11-1216:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001725160-24-000173 |
| 2024-09-1607:02 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001725160-24-000161 |
| 2024-08-0907:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001725160-24-000158 |
| 2024-08-0907:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001725160-24-000157 |
| 2024-06-2117:06 ET | 8-K | 5.07 Shareholder vote results | 0001725160-24-000140 |
| 2024-06-0307:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-24-000131 |
| 2024-05-2907:04 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001725160-24-000120 |
| 2024-05-0707:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001725160-24-000107 |
| 2024-05-0707:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001725160-24-000106 |
| 2024-04-2916:34 ET | DEF 14A | Proxy statementPeriod 2024-06-21 | 0001725160-24-000096 |
| 2024-04-1107:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001725160-24-000087 |
| 2024-04-0916:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001725160-24-000082 |
| 2024-02-2707:08 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001725160-24-000080 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:29 ET. Listed shows no prices and gives no investment advice.